365 related articles for article (PubMed ID: 27286189)
41. Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.
Song YF; Liu DZ; Cheng Y; Liu M; Ye WL; Zhang BL; Liu XY; Zhou SY
Sci Rep; 2015 Nov; 5():16125. PubMed ID: 26530454
[TBL] [Abstract][Full Text] [Related]
42. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
Du H; Liu M; Yu A; Ji J; Zhai G
Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815
[TBL] [Abstract][Full Text] [Related]
43. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model.
Jain AK; Swarnakar NK; Das M; Godugu C; Singh RP; Rao PR; Jain S
Mol Pharm; 2011 Aug; 8(4):1140-51. PubMed ID: 21557558
[TBL] [Abstract][Full Text] [Related]
44. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
45. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
46. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
47. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
48. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
49. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Cui T; Zhang S; Sun H
Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
[TBL] [Abstract][Full Text] [Related]
50. pH-Responsive prodrug nanoparticles based on a sodium alginate derivative for selective co-release of doxorubicin and curcumin into tumor cells.
Gao C; Tang F; Gong G; Zhang J; Hoi MPM; Lee SMY; Wang R
Nanoscale; 2017 Aug; 9(34):12533-12542. PubMed ID: 28819666
[TBL] [Abstract][Full Text] [Related]
51. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
Chang JE; Shim WS; Yang SG; Kwak EY; Chong S; Kim DD; Chung SJ; Shim CK
Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
[TBL] [Abstract][Full Text] [Related]
52. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
[TBL] [Abstract][Full Text] [Related]
54. Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles.
Augustin E; Czubek B; Nowicka AM; Kowalczyk A; Stojek Z; Mazerska Z
Toxicol In Vitro; 2016 Jun; 33():45-53. PubMed ID: 26911730
[TBL] [Abstract][Full Text] [Related]
55. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency.
Li W; Fu J; Ding Y; Liu D; Jia N; Chen D; Hu H
Acta Biomater; 2019 Sep; 96():456-467. PubMed ID: 31260821
[TBL] [Abstract][Full Text] [Related]
56. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
Kong F; Tang C; Yin C
Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
[TBL] [Abstract][Full Text] [Related]
57. Doxorubicin hydrochloric increases tumour coagulation and end-point survival in percutaneous microwave ablation of tumours in a VX2 rabbit tumour model.
Song X; Liang M; Zhou W; Ren L; Liu Z; Wang G; Wei Q; Wang S
Int J Hyperthermia; 2016 May; 32(3):265-71. PubMed ID: 26905817
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
60. A small molecule nanodrug consisting of pH-sensitive ortho ester-dasatinib conjugate for cancer therapy.
Gao J; Qiao Z; Liu S; Xu J; Wang S; Yang X; Wang X; Tang R
Eur J Pharm Biopharm; 2021 Jun; 163():188-197. PubMed ID: 33864903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
